TFF2 Polyclonal Antibody, Biotin, PeproTech®, Invitrogen™

Description

• AA Sequence of recombinant protein: AEKPSPCQCS RLSPHNRTNC GFPGITSDQC FDNGCCFDSS VTGVPWCFHP LPKQESDQCV MEVSDRRNCG YPGISPEECA SRKCCFSNFI FEVPWCFFPK SVEDCHY
• Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human TFF-2
• Anti-Human TFF-2-specific antibody was purified by affinity chromatography and then biotinylated
• Sandwich ELISA: To detect Human TFF-2 by sandwich ELISA (using 100 μL/well) a concentration of 0.25-1.0 μg/mL of this antibody is required
• This biotinylated polyclonal antibody, in conjunction with PeproTech Polyclonal Anti- Human TFF-2 (500-P312) as a capture antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human TFF-2
• Western Blot: To detect Human TFF-2 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL
• When used in conjunction with compatible development reagents the detection limit for Recombinant Human TFF-2 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions
• 500-P312BT-1MG will be provided as 2 x 500 μg Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing and protection of the gastrointestinal epithelia
• These peptides contain three intrachain disulfide bonds, forming the trefoil motif, or P-domain
• SP (spasmolytic polypeptide), also designated Trefoil factor 2 (TFF2) precursor, is a trefoil protein that functions to inhibit gastrointestinal motility and gastric acid secretion
• SP may also act as a structural component of the gastric mucus, possibly by stabilizing glycoproteins in the mucus gel through interactions with carbohydrate side chains
• A downregulation of SP expression is associated with primary gastric cancer, and a progressive loss of this protein is likely to be involved in the early stage of the multi-step gastric carcinogenesis pathway.